Oral Delivery of 1,3‐Dicyclohexylurea Nanosuspension Enhances Exposure and Lowers Blood Pressure in Hypertensive Rats
Open Access
- 12 March 2008
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 102 (5), 453-458
- https://doi.org/10.1111/j.1742-7843.2008.00213.x
Abstract
Cytochrome P450-derived epoxyeicosatrienoic acids (EET) are biologically active metabolites of arachidonic acid that have potent effects on renal vascular reactivity and tubular ion transport and have been implicated in the control of blood pressure. EETs are hydrolyzed to their less active diols, dihydroxyeicosatrienoic acids (DHET), by the enzyme soluble epoxide hydrolase (sEH). 1,3-Dicyclohexylurea (DCU), a potent sEH inhibitor, lowers systemic blood pressure in spontaneously hypertensive rats when dosed intraperitoneally. However, DCU has poor aqueous solubility, posing a challenge for in vivo oral delivery. To overcome this limitation, we formulated DCU in a nanosuspension using wet milling. Milling reduced particle size, increasing the total surface area by approximately 40-fold. In rats chronically infused with angiotensin II, the DCU nanosuspension administered orally twice daily for 4 days produced plasma exposures an order of magnitude greater than unmilled DCU and lowered blood pressure by nearly 30 mmHg. Consistent with the mechanism of sEH inhibition, DCU increased plasma 14,15-EET and decreased plasma 14,15-DHET levels. These data confirm the antihypertensive effect of sEH inhibition and demonstrate that greatly enhanced exposure of a low-solubility compound is achievable by oral delivery using a nanoparticle drug delivery system.This publication has 37 references indexed in Scilit:
- Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2006
- Cytochrome and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisitedCardiovascular Research, 2005
- Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseasesAmerican Journal of Physiology-Renal Physiology, 2005
- 14,15-Epoxyeicosatrienoic Acid Represents a Transferable Endothelium-Dependent Relaxing Factor in Bovine Coronary ArteriesHypertension, 2005
- Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2005
- P450-Dependent Arachidonic Acid Metabolism and Angiotensin II–Induced Renal DamageHypertension, 2002
- The CYP P450 Arachidonic Acid Monooxygenases: From Cell Signaling to Blood Pressure RegulationBiochemical and Biophysical Research Communications, 2001
- Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet.JCI Insight, 1994
- Effect of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive ratsBiochemical and Biophysical Research Communications, 1990
- Experiments on the toxic, sedative and muscle relaxant potency of various drug solvents in micePharmacology & Therapeutics, 1979